The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Yonsei University
Age
19–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
1. age\> 19 years
2. ECOG performance status 0-1
3. pathologically confirmed malignant epithelial ovarian cancer
4. surgically removal of tumor including both ovary resection, total hysterectomy, lymph node and mesentery
5. at least on of the following: consolidation therapy for grossly negative condition prior large tumor after surgery and adjuvant chemotherapy, residual tumor after adjuvant or salvage chemotherapy, local recurrent tumor after adjuvant or salvage chemotherapy, consolidation therapy after surgical removal of recurrent tumor
You may not be if
1. diffuse peritoneal seeding
2. brain or bone metastasis
3. prior invasive malignancy (except controlled skin cancer, carcinoma in situ of the cervix and early thyroid and gastric cancer) unless disease free for a minimum of 5 years prior to study entry
4. serious underlying medical disease
5. not providing informed consent
Clareo Health | The Efficacy of Involved-field Radiation Therapy for Residual or Locoregionally Recurrent Epithelial Ovarian Cancer After Definitive Treatment; Multi-institutional Clinical Trial
